Brian D. Palmer

Prof. Dr. Brian D. Palmer


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BPBrian D. Palmer
Brian D. Palmer
ATAndrew M. Thompson
Andrew M. Thompson
RBR. John Booth
R. John Booth
EDEllen M. Dobrusin
Ellen M. Dobrusin
AKAlan J. Kraker
Alan J. Kraker
WDWilliam A. Denny
William A. Denny

17 December 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ATAndrew M. Thompson
Andrew M. Thompson
ABAdrian Blaser
Adrian Blaser
RARobert F. Anderson
Robert F. Anderson
SSSujata S. Shinde
Sujata S. Shinde
SFScott Franzblau
Scott Franzblau
BPBrian D. Palmer
Brian D. Palmer

1 April 2005 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BPBrian D. Palmer
Brian D. Palmer
JSJeff B. Smaill
Jeff B. Smaill
GRGordon W. Rewcastle
Gordon W. Rewcastle
EDEllen M. Dobrusin
Ellen M. Dobrusin
AKAlan Kraker
Alan Kraker
WDWilliam A. Denny
William A. Denny

20 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
PCPeter Choi
Peter Choi
DCDaniel Conole
Daniel Conole
HSHamish S. Sutherland
Hamish S. Sutherland
ABAdrian Blaser
Adrian Blaser
ATAmy S.T. Tong
Amy S.T. Tong
BDBill Denny
Bill Denny
Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compound with an associated long terminal half-life and shows potent inhibition of the cardiac potassium hERG channel, resulting in QTc interval prolongation in humans that may result in cardiac arrhythmia. To address these issues, we carried out a drug discovery programme to develop an improved second generation analogue of bedaquiline. From this medicinal chemistry program, a candidate (TBAJ-876) has been selected to undergo further preclinical evaluation. During this evaluation, three major metabolites arising from TBAJ-876 were observed in several preclinical animal models. We report here our synthetic efforts to unequivocally structurally characterize these three metabolites through their independent directed synthesis.

1 June 2021 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RIRossella Capochiani de Iudicibus
Rossella Capochiani de Iudicibus
PTPetr Tomek
Petr Tomek
BPBrian D. Palmer
Brian D. Palmer
STSofian M Tijono
Sofian M Tijono
JFJack U. Flanagan
Jack U. Flanagan
LCLai-Ming Ching
Lai-Ming Ching

1 April 1987 in Synthetic Communications
Verified
Journal Article
Closed access
BPBrian D. Palmer
Brian D. Palmer
BDBill Denny
Bill Denny
Reaction of aromatic and heteroaromatic halides with 3-pyrroline gives adducts which can be converted in a three-step process to nitrogen mustards.